Key Points
- Johnson & Johnson EVP Elizabeth Forminard sold 13,072 shares for about $3.72 million, reducing her stake by 43.48%; she retained 16,994 shares after the transaction.
- Latest quarterly results slightly beat estimates: adjusted earnings were $2.59 per share versus $2.53 expected, while revenue reached $25.40 billion, up 5.9% year over year. J&J set 2026 EPS guidance at $11.05–$11.15.
- The company declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield at the article’s cited share price. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $275.92.
Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Elizabeth Forminard sold 13,072 shares of the business's stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Johnson & Johnson Trading Up 0.8%
Johnson & Johnson stock traded up $2.26 during mid-day trading on Friday, hitting $285.78. The company's stock had a trading volume of 6,279,519 shares, compared to its average volume of 7,472,752. The company has a 50 day moving average of $266.97 and a 200-day moving average of $249.85. The stock has a market cap of $687.95 billion, a PE ratio of 43.30, a P/E/G ratio of 2.80 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the firm posted $2.80 earnings per share. The business's revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is currently 81.21%.
Hedge Funds Weigh In On Johnson & Johnson
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson in the second quarter worth about $28,000. Matrix Trust Co increased its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC raised its holdings in shares of Johnson & Johnson by 60.4% in the 3rd quarter. Navigoe LLC now owns 146 shares of the company's stock valued at $38,000 after purchasing an additional 55 shares in the last quarter. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on JNJ. Guggenheim reiterated a "buy" rating and set a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. TD Cowen restated a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Royal Bank Of Canada reduced their target price on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. Citigroup lifted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a research note on Monday, October 5th. Finally, Bank of America reaffirmed a "neutral" rating and set a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $275.92.
Check Out Our Latest Research Report on JNJ
More Johnson & Johnson News
Investors following JNJ have been watching these news items:
Johnson & Johnson Company Profile
(
Get Free Report)
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
